Abstract
Background The statistical analysis of composite outcomes is challenging. The Clinical Outcomes, HEalthcare REsource utilizatioN, and relaTed costs (COHERENT) model was developed to describe and compare all components (incidence, timing and duration) of composite outcomes, but its statistical analysis remained unsolved. The aim of the study is to assess a multi-State Markov model as one statistical solution for the COHERENT model.
Methods A cohort of 3280 patients admitted to the emergency department or hospital for heart failure during year 2018 were followed during one year. The state of the patient was registered at the end of each day during 365 days as: home, emergency department (ED), hospital, re-hospital, re-ED, and death. Outcomes of patients with or without severe renal disease (sRD) were compared as an example. A Multi-State Markov model was developed to explain transitions to and from these states during follow-up.
Results A Multi-State Markov model showed, adjusted for age and sex, a significantly lower likelihood of patients with sRD to return home regardless of the state in which they were (ED → HOME (HR, 0.72; 95%CI, 0.54-0.95), RE-ED → HOME (HR, 0.83; 95%CI, 0.75-0.93), HOSPITAL → HOME (HR, 0.77; 95%CI, 0.69-0.86), RE-HOSPITAL → HOME (HR, 0.82; 95%CI, 0.74-0.92) and a higher mortality risk, in particular at the hospital and at home (HOME → Death [HR, 1.54; 95%CI, 1.01-2.37] and HOSPITAL → Death [HR, 1.71; 95%CI, 1.30-2.24].
Conclusion Multi-state Markov models offer a statistical solution for the comprehensive analysis of composite outcomes assessed as transitions from different clinical states.
Clinical Perspective
What is new?
An integrated analysis of all components of composite endpoints including its incidence and duration is possible using the COHERENT model with analysis of transition risks.
A statistical approach based on Markov chain models is a new potential statistical solution for the multivariate estimation of the risk of transitions in mutually exclusive composite endpoints.
What are the clinical implications?
The use of the COHERENT model and Markov models is an opportunity to analyze composite endpoints and understand better the relationships between its components and, potentially, to improve the performance of statistical analysis in randomized controlled trials.
The utilization of the COHERENT model and Markov models in randomized controlled trials should be validated in future observational studies and in randomized controlled trials.
Competing Interest Statement
This study was an investigator initiative sponsored by AstraZeneca Spain. Dr. Bueno receives research funding from the Instituto de Salud Carlos III, Spain (PIE16/00021 & PI17/01799, PI21/01572), Sociedad Española de Cardiología, AstraZeneca, Boehringer Ingelheim, Janssen, and Novartis; has received consulting/speaking fees from Astra-Zeneca, Novartis, Novo Nordisk and Organon: and was a scientific advisor for MEDSCAPE-the heart.org. Beatriz Palacios, Miriam Villarreal, and Margarita Capel are employees of AstraZeneca Spain.
Clinical Trial
N/A
Funding Statement
This work was supported by AstraZeneca Farmacéutica Spain, S.A
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Hospital Universitario 12 de Octubre institutional review board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Original data come from the hospital information system. This is not available. Data from the anonimzed edited database may be accessible after reasonable request.
Non-standard Abbreviations and Acronyms
- HF
- Heart failure
- COHERENT
- Clinical Outcomes, HEalthcare REsource utilizatioN, and relaTed costs
- CI
- Confidence Interval
- ED
- Emergency department sRD: Severe renal disease
